Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC
Journal
JTO clinical and research reports
Journal Volume
4
Journal Issue
11
Date Issued
2023-11
Author(s)
Kim, Hye Ryun
Awad, Mark M
Navarro, Alejandro
Gottfried, Maya
Peters, Solange
Csőszi, Tibor
Cheema, Parneet K
Rodriguez-Abreu, Delvys
Wollner, Mirjana
Mazieres, Julien
Orlandi, Francisco J
Luft, Alexander
Gümüş, Mahmut
Kato, Terufumi
Kalemkerian, Gregory P
Luo, Yiwen
Santorelli, Melissa L
Pietanza, M Catherine
Rudin, Charles M
Abstract
In the phase 3 KEYNOTE-604 study (NCT03066778), pembrolizumab plus etoposide and platinum chemotherapy (EP) significantly (p = 0.0023) improved progression-free survival versus placebo plus EP in previously untreated extensive-stage SCLC (ES-SCLC). We present health-related quality of life (HRQoL) results from KEYNOTE-604.
Subjects
Chemotherapy; Extensive-stage small-cell lung cancer; Health-related quality of life; Patient-reported outcomes; Pembrolizumab
SDGs
Type
journal article